Clinical Trial Update: A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss [Phase 2]

View source ↗

Summary

Phase II single-arm neoadjuvant trial evaluating intensified androgen deprivation with leuprolide and abiraterone acetate plus the AKT inhibitor capivasertib in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Abiraterone acetate (Abiraterone acetate)
• Capivasertib (capivasertib)
• Leuprolide (Leuprolide acetate)

Snippet

Sponsor: VA Office of Research and Development | Conditions: High-Risk Prostate Cancer | Phase 2 | Status: RECRUITING